Liraglutide

Generic Name
Liraglutide
Brand Names
Saxenda, Victoza, Xultophy
Drug Type
Biotech
Chemical Formula
-
CAS Number
204656-20-2
Unique Ingredient Identifier
839I73S42A
Background

Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.

Indication

Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.

Victoza, a formulation of liraglutide used in diabetes, is indicated as an adjunct to diet and exercise to improve glycemic control in patients ≥10 years old with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes and established cardiovascular disease.

Liraglutide is also available in combination with insulin degludec as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Associated Conditions
Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
Associated Therapies
Chronic Weight Management therapy

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

First Posted Date
2011-12-02
Last Posted Date
2018-11-01
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
1344
Registration Number
NCT01484262
Locations
🇩🇪

Novo Nordisk Investigational Site, Mainz, Germany

The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-11-16
Last Posted Date
2015-10-12
Lead Sponsor
Flyvbjerg, Allan, DMSc
Target Recruit Count
240
Registration Number
NCT01472640
Locations
🇩🇰

Skejby University Hospital, Aarhus, Denmark

🇩🇰

Steno Diabetes Center, Gentofte, Denmark

🇩🇰

Herlev University Hospital, Herlev, Denmark

and more 1 locations

Identifying Potential Effects of Liraglutide on Degenerative Changes

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-11-10
Last Posted Date
2013-04-19
Lead Sponsor
University of Aarhus
Target Recruit Count
34
Registration Number
NCT01469351
Locations
🇩🇰

Aarhus University, Aarhus, Denmark

The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-10-26
Last Posted Date
2013-06-21
Lead Sponsor
Annesofie Faurschou
Target Recruit Count
20
Registration Number
NCT01460069
Locations
🇩🇰

Gentofte Hospital, Hellerup, Denmark

GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

First Posted Date
2011-10-14
Last Posted Date
2012-06-21
Lead Sponsor
University Hospital, Gentofte, Copenhagen
Target Recruit Count
12
Registration Number
NCT01451905
Locations
🇩🇰

Gentofte Hospital, Hellerup, Denmark

Liraglutide and Heart Failure in Type 2 Diabetes

First Posted Date
2011-08-30
Last Posted Date
2016-09-01
Lead Sponsor
Thomas Nystrom
Target Recruit Count
62
Registration Number
NCT01425580
Locations
🇸🇪

Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden

🇸🇪

Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB, Stockholm, Sweden

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

First Posted Date
2011-07-27
Last Posted Date
2018-02-12
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
4121
Registration Number
NCT01403025
Locations
🇯🇵

Novo Nordisk Investigational Site, Tokyo, Japan

Liraglutide Treatment to Patients With Severe Renal Insufficiency

First Posted Date
2011-07-14
Last Posted Date
2013-10-09
Lead Sponsor
Bo Feldt-Rasmussen
Target Recruit Count
40
Registration Number
NCT01394341
Locations
🇩🇰

Department of Endocrinology PE, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Copenhagen, Denmark

🇩🇰

Department of Nephrology P, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Copenhagen, Denmark

🇩🇰

Department of Internal Medicine H, Hillerød Hospital, Hillerød, Denmark

Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes

Not Applicable
Conditions
Interventions
First Posted Date
2011-07-13
Last Posted Date
2013-08-02
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
50
Registration Number
NCT01392898
Locations
🇳🇱

Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

First Posted Date
2011-07-06
Last Posted Date
2017-03-06
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
413
Registration Number
NCT01388361
Locations
🇪🇸

Novo Nordisk Investigational Site, Sevilla, Spain

© Copyright 2024. All Rights Reserved by MedPath